Anti-PD-1-CTLA4 Combo Hits Prostate Cancer.
Combining nivolumab and ipilimumab may be an effective treatment strategy for metastatic castration-resistant prostate cancer. In a phase II trial, 25% of patients who received the combination following hormone therapy had an objective response. However, the combination was associated with considerable side effects that caused many patients to discontinue treatment.